Avalanche Biotechnologies Inc  

(Public, NASDAQ:AAVL)   Watch this stock  
Find more results for Paul Wachter
Dec 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 22.00 - 54.17
Open     -
Vol / Avg. 0.00/166,194.00
Mkt cap 1.16B
P/E     -
Div/yield     -
EPS -1.02
Shares 22.47M
Beta     -
Inst. own 65%
Dec 3, 2014
Avalanche Biotechnologies Inc at the 26th Annual Piper Jaffray Healthcare Conference
Nov 20, 2014
Avalanche Biotechnologies Inc at Jefferies Global Healthcare Conference - London
Nov 6, 2014
Avalanche Biotechnologies Inc at Nomura Biotechnology Conference
Oct 8, 2014
Avalanche Biotechnologies Inc at BIO Investor Forum
Sep 26, 2014
Avalanche Biotechnologies Inc at BioCentury Publications NewsMakers in the Biotech Industry
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -4047.06% -1099.17%
Operating margin -3892.16% -1067.71%
EBITD margin - -547.50%
Return on average assets -29.83% -717.34%
Return on average equity -47.57% -
Employees 26 -
CDP Score - -


1035 O?Brien Drive, Suite A
United States - Map
+1-650-2726269 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Avalanche Biotechnologies, Inc. (Avalanche) is a biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanche has leveraged its next generation gene therapy platform, the Ocular BioFactory, to create a robust pipeline of product candidates. Its product candidates are designed to provide long-term benefit or a functional cure for these diseases by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye. The Company´┐Żs products include AVA-101, AVA-201, AVA-311, AVA-322 and AVA-323. AMD is a progressive disease affecting the retinal cells in the macula, the region of the eye responsible for central vision. Disease progression results in the death of retinal cells and the gradual loss of vision. As people age, the likelihood of disease progression increases and the resulting condition is referred to as AMD.

Officers and directors

Mark S. Blumenkranz M.D. Chairman of the Board, Co-Founder
Bio & Compensation  - Reuters
Thomas W. Chalberg Jr., Ph.D. President, Chief Executive Officer, Director
Age: 36
Bio & Compensation  - Reuters
Steven D. Schwartz M.D. Co-Founder, Director
Age: 52
Bio & Compensation  - Reuters
Linda C. Bain CPA Chief Financial Officer, Treasurer
Age: 43
Bio & Compensation  - Reuters
Hans P. Hull J.D. Senior Vice President - Legal and Corporate Development
Age: 39
Bio & Compensation  - Reuters
Roman G Rubio M.D. Senior Vice President and Head - Translational Medicine
Bio & Compensation  - Reuters
Mehdi Gasmi Ph.D. Vice President - Pharmaceutical Development
Age: 47
Bio & Compensation  - Reuters
Samuel B. Barone M.D. Chief Medical Officer
Age: 40
Bio & Compensation  - Reuters
John P. McLaughlin Director
Bio & Compensation  - Reuters
Paul D. Wachter Director
Age: 57
Bio & Compensation  - Reuters